Correlation Between Alnylam Pharmaceuticals and Exelixis

Can any of the company-specific risk be diversified away by investing in both Alnylam Pharmaceuticals and Exelixis at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Alnylam Pharmaceuticals and Exelixis into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Alnylam Pharmaceuticals and Exelixis, you can compare the effects of market volatilities on Alnylam Pharmaceuticals and Exelixis and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Alnylam Pharmaceuticals with a short position of Exelixis. Check out your portfolio center. Please also check ongoing floating volatility patterns of Alnylam Pharmaceuticals and Exelixis.

Diversification Opportunities for Alnylam Pharmaceuticals and Exelixis

-0.34

Correlation Coefficient

Alnylam Pharmaceuticals  Exelixis

Very good diversification

The 3 months correlation between Alnylam and Exelixis is -0.34. Overlapping area represents the amount of risk that can be diversified away by holding Alnylam Pharmaceuticals and Exelixis in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Exelixis and Alnylam Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Alnylam Pharmaceuticals are associated (or correlated) with Exelixis. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Exelixis has no effect on the direction of Alnylam Pharmaceuticals i.e., Alnylam Pharmaceuticals and Exelixis go up and down completely randomly.

Pair Corralation between Alnylam Pharmaceuticals and Exelixis

Given the investment horizon of 90 days Alnylam Pharmaceuticals is expected to generate 24.45 times less return on investment than Exelixis. But when comparing it to its historical volatility, Alnylam Pharmaceuticals is 1.12 times less risky than Exelixis. It trades about 0.01 of its potential returns per unit of risk. Exelixis is currently generating about 0.23 of returns per unit of risk over similar time horizon. If you would invest  2,561  in Exelixis on September 4, 2024 and sell it today you would earn a total of  998.00  from holding Exelixis or generate 38.97% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Alnylam Pharmaceuticals  vs.  Exelixis

Alnylam Pharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Alnylam Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Alnylam Pharmaceuticals is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors.

Exelixis

Risk-Adjusted Performance

17 of 100

Solid

Compared to the overall equity markets, risk-adjusted returns on investments in Exelixis are ranked lower than 17 (%) of all global equities and portfolios over the last 90 days. Despite quite weak technical and fundamental indicators, Exelixis disclosed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Alnylam Pharmaceuticals and Exelixis

The main advantage of trading using opposite Alnylam Pharmaceuticals and Exelixis positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Alnylam Pharmaceuticals position performs unexpectedly, Exelixis can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Exelixis will offset losses from the drop in Exelixis' long position.

The idea behind Alnylam Pharmaceuticals and Exelixis pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.